Tropifexor (LJN452)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Non-alcoholic Steatohepatitis (NASH)

Phase 2

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

TerminatedNCT02855164

Novartis PharmaceuticalsNon-alcoholic Steatohepatitis (NASH)

Start: 2016-08-01End: 2020-04-06Updated: 2021-09-05

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

CompletedNCT03517540

Novartis PharmaceuticalsNon-alcoholic Steatohepatitis (NASH)

Start: 2018-09-11End: 2020-10-15Updated: 2022-04-29

Related Papers

NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials.

2025-01-019 citations

Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.

2024-11-289 citations

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis.

2023-07-146 citations

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.

2023-02-16115 citations

Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH.

2022-06-3084 citations

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.

2019-11-1389 citations